PTAB Finds Favor In Court; Novartis Is Latest To Strike Out In Challenge
Federal Circuit affirms US Patent Trial and Appeal Board decision against Gilenya composition patent a week after upholding board decision on Exelon Patch patents; court has reviewed 200 PTAB decisions and affirmed 158 of them.
You may also be interested in...
A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.
Federal Circuit rejects Novartis argument that Patent Trial and Appeal Board unlawfully concluded Exelon patents were unpatentable after a district court upheld them.
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.